Scholarlink

<p>Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become an established treatment for selected peritoneal surface malignancies. However, awareness, training exposure, and attitudes toward CRS–HIPEC vary among oncologic disciplines. This nation sample study aimed to assess and compare the knowledge, awareness, and perceptions of surgical and medical oncologists in Türkiye regarding CRS–HIPEC indications, benefits, and implementation. A cross-sectional, web-based survey was conducted between July and December 2025 among certified surgical and medical oncologists. A 19-item questionnaire evaluated demographics, CRS–HIPEC training exposure, institutional practices, and attitudes using a five-point Likert scale. A total of 98 oncologists participated (50 surgical, 48 medical), corresponding to an overall response rate of 36.3%. HIPEC-related training was significantly more common among surgical oncologists (39/50, 78% vs 13/48, 27%; <i>p</i> &lt; 0.001), as were higher self-rated knowledge levels (<i>p</i> &lt; 0.001) and awareness of CRS–HIPEC indications (40/50, 80% vs 28/48, 58%; <i>p</i> = 0.035). Agreement with the statement that CRS–HIPEC improves survival in appropriately selected patients was also stronger among surgical oncologists (44/50, 88% vs 35/48, 73%; <i>p</i> = 0.006). Among medical oncologists, those participating in multidisciplinary tumor boards were more likely to agree with the survival benefit (<i>p</i> = 0.032). Overall, 92% of participants supported the need for a national CRS–HIPEC guideline or standardized protocol. Surgical oncologists report greater training exposure and stronger belief in the benefit of CRS–HIPEC; however, multidisciplinary collaboration enhances understanding and acceptance among medical oncologists. Unified national guidelines and structured training programs may help align perspectives and optimize multidisciplinary practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Awareness and attitudes toward cytoreductive surgery and hyperthermic intraperitoneal chemotherapy among surgical and medical oncologists

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月10日

查看全文
  • Erkan Güler,
  • Ali Oğul,
  • Volkan Sayur,
  • Sami Benli,
  • Cumhur Özcan,
  • Tahsin Çolak,
  • Mehmet Özgür Türkmenoğlu,
  • Najmaddin Abbasli

摘要

Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become an established treatment for selected peritoneal surface malignancies. However, awareness, training exposure, and attitudes toward CRS–HIPEC vary among oncologic disciplines. This nation sample study aimed to assess and compare the knowledge, awareness, and perceptions of surgical and medical oncologists in Türkiye regarding CRS–HIPEC indications, benefits, and implementation. A cross-sectional, web-based survey was conducted between July and December 2025 among certified surgical and medical oncologists. A 19-item questionnaire evaluated demographics, CRS–HIPEC training exposure, institutional practices, and attitudes using a five-point Likert scale. A total of 98 oncologists participated (50 surgical, 48 medical), corresponding to an overall response rate of 36.3%. HIPEC-related training was significantly more common among surgical oncologists (39/50, 78% vs 13/48, 27%; p < 0.001), as were higher self-rated knowledge levels (p < 0.001) and awareness of CRS–HIPEC indications (40/50, 80% vs 28/48, 58%; p = 0.035). Agreement with the statement that CRS–HIPEC improves survival in appropriately selected patients was also stronger among surgical oncologists (44/50, 88% vs 35/48, 73%; p = 0.006). Among medical oncologists, those participating in multidisciplinary tumor boards were more likely to agree with the survival benefit (p = 0.032). Overall, 92% of participants supported the need for a national CRS–HIPEC guideline or standardized protocol. Surgical oncologists report greater training exposure and stronger belief in the benefit of CRS–HIPEC; however, multidisciplinary collaboration enhances understanding and acceptance among medical oncologists. Unified national guidelines and structured training programs may help align perspectives and optimize multidisciplinary practice.